Neuphoria Therapeutics Inc(NEUP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:10 PM ET (Korea 9/12 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 7.7% | Shs Outstand | - | Perf Week | -0.8% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | -1.23% | Insider Trans | - | Shs Float | 5.0M | Perf Month | -2.1% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 40.94% | Short Float | 1.3% | Perf Quarter | -16.93% |
| Income | - | P/S | - | EPS this Y | 40.29% | Inst Trans | 7.45% | Short Ratio | 0.34 | Perf Half Y | -21.14% |
| Sales | - | P/B | 0.68 | EPS next 5Y | - | ROA | - | Short Interest | 0.06M | Perf YTD | -3.87% |
| Book/sh | 5.47 | P/C | 1.04 | EPS past 3/5Y | -17.62% -20.01% | ROE | - | 52W High | -82.57% ($21.40) | Perf Year | -73.34% |
| Cash/sh | 3.6 | P/FCF | - | Sales past 3/5Y | 334.17% 246.61% | ROIC | - | 52W Low | 16.93% ($3.19) | Perf 3Y | -83.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -15957.73% | Gross Margin | - | Volatility(W/M) | 2.55% 3.47% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.31 | EPS Q/Q | 92.44% | Profit Margin | - | RSI (14) | 42.45 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.31 | Sales Q/Q | -100% | SMA20 | -2.46% ($3.82) | Beta | 0.74 | Target Price | $7 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -0.04% ($3.73) | Rel Volume | 0.12 | Prev Close | $3.73 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -12.61% ($4.27) | Avg Volume(3M) | 0.19M | Price | $3.73 |
| IPO | 2021/12/16 | Option/Short | No/Yes | Trades | 122 | Volume | 23,044 | Change | - |
Company
NEUP is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 Neuphoria Therapeutics () is a clinical-stage biotech developing oral anti-anxiety and neuropsychiatric therapies that target the α7 nicotinic receptor. Its lead candidate, BNC210, suffered a setback when it failed to meet the primary endpoint in the Phase 3 social anxiety disorder (SAD) trial, but the company is regrouping around the Phase 2b SYMPHONY trial in post-traumatic stress disorder (PTSD) and its Alzheimer's PAM partnership (MK-1167) with Merck (MRK), making it a small-cap neuroscience biotech play.
Over the past 1 year, on the lower side
83% below its 1-year high.
NEUP makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +40.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Generally in line with estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -83.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 40.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PSIL 0.02%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $20M.
NEUP $20M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is NEUP?
NEUP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NEUP?
The market cap of NEUP is approximately $20M, ranking 5,282 within its sector.
What is the 52-week high and low for NEUP?
NEUP has recorded a 52-week high of $21.40 and a low of $3.19.
